(Q34123874)

31 July 2017

1 reference

title

The hyper-CVAD regimen in adult acute lymphocytic leukemia (English)

1 reference

31 July 2017

0 references

1 reference

Garcia-Manero G

1

1 reference

PubMed ID

11147229

31 July 2017

Kantarjian HM

series ordinal

2

1 reference

31 July 2017

1 December 2000

1 reference

Hematology / Oncology Clinics of North America

31 July 2017

1 reference

31 July 2017

14

1 reference

31 July 2017

1381-96, x-xi

1 reference

31 July 2017

6

1 reference

The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970192-1

7 January 2021

Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970192-1

7 January 2021

Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970192-1

7 January 2021

A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970192-1

7 January 2021

Cell kinetics in Burkitt lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970192-1

7 January 2021

Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970192-1

7 January 2021

Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970192-1

7 January 2021

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970192-1

7 January 2021

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970192-1

7 January 2021

Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970192-1

7 January 2021

Radiotherapy in Burkitt's lymphoma: conventional or superfractionated regime--early results

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970192-1

7 January 2021

Acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970192-1

7 January 2021

Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970192-1

7 January 2021

Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970192-1

7 January 2021

10.1016/S0889-8588(05)70192-1

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11147229